Artificial Intelligence-Enabled Next-Generation Clinical Trials: Improving Drug Development Efficiency and Adaptive Trial Design

Authors

Nitesh Prasad Sah

Department of Clinical Research, Fortis Flt Lt. Rajan Dhall Hospital New Delhi (India)

Article Information

DOI: 10.51244/IJRSI.2026.1303000054

Subject Category: Artificial Intelligence

Volume/Issue: 13/3 | Page No: 618-621

Publication Timeline

Submitted: 2026-03-12

Accepted: 2026-03-17

Published: 2026-03-28

Abstract

Clinical trials play a vital role in evaluating the safety and effectiveness of new medical treatments. However, conventional trial methods often face several challenges, including high operational costs, extended timelines, and difficulties in recruiting appropriate participants (6). In recent years, Artificial Intelligence (AI) has emerged as a promising technology capable of addressing many of these limitations (1,2). AI-based tools can rapidly process large volumes of medical data, identify suitable patient populations, and support more efficient trial management (3,4). Additionally, machine learning techniques can assist researchers in predicting treatment responses and detecting potential safety concerns at earlier stages (5,17). Despite these advantages, issues related to data privacy, algorithm transparency, and ethical considerations remain important topics of discussion (16,19). This review explores current applications of AI in clinical trials, its benefits in improving research efficiency, and the potential future direction of AI-driven clinical research. In countries such as India, where healthcare data is extensive yet often fragmented, the integration of AI could significantly enhance the drug development process.

Keywords

Artificial Intelligence, Clinical Trials, Machine Learning, Drug Development, Digital Health

Downloads

References

1. Jiang F, Jiang Y, Zhi H, et al. Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2017;2(4):230-243. doi:10.1136/svn-2017-000101. [Google Scholar] [Crossref]

2. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44-56. doi:10.1038/s41591-018-0300-7. [Google Scholar] [Crossref]

3. Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends Pharmacol Sci. 2019;40(8):577-591. doi:10.1016/j.tips.2019.05.005. [Google Scholar] [Crossref]

4. Paul D, Sanap G, Shenoy S, et al. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021;26(1):80-93. doi:10.1016/j.drudis.2020.10.010. [Google Scholar] [Crossref]

5. Mak KK, Pichika MR. Artificial intelligence in drug development. Drug Discov Today. 2019;24(3):622-628. doi:10.1016/j.drudis.2018.11.014. [Google Scholar] [Crossref]

6. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273-286. doi:10.1093/biostatistics/kxx069. [Google Scholar] [Crossref]

7. Bhatt A. Artificial intelligence in clinical health care applications: Viewpoint. Perspect Clin Res. 2020;11(2):92-95. doi:10.4103/picr.PICR_175_19. [Google Scholar] [Crossref]

8. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-477. doi:10.1038/s41573-019-0024-5. [Google Scholar] [Crossref]

9. Torkamani A, Andersen KG, Steinhubl SR, Topol EJ. High-Definition Medicine. Cell. 2017;170(5):828-843. doi:10.1016/j.cell.2017.08.007. [Google Scholar] [Crossref]

10. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436-444. doi:10.1038/nature14539. [Google Scholar] [Crossref]

11. Mullard A. Can second-generation AI tools deliver on the drug discovery hype? Nat Rev Drug Discov. 2022;21(9):623-625. doi:10.1038/d41573-022-00140-5. [Google Scholar] [Crossref]

12. Askin S, Burkhalter D, Calado G, El Dakak R. Outcomes of Clinical Trials in Drug Development. Stem Cell Rev Rep. 2017;13(3):358-369. doi:10.1007/s12015-017-9741-z. [Google Scholar] [Crossref]

13. Izmailov R, Lin M, Lumish M, et al. Artificial intelligence for clinical trial enrollment. NPJ Digit Med. 2021;4(1):145. doi:10.1038/s41746-021-00518-x. [Google Scholar] [Crossref]

14. Steinhubl SR, Wolff-Cassingham P, Guzman J, et al. Digital health and artificial intelligence in clinical research. Digital Health. 2022;8:20552076221105342. [Google Scholar] [Crossref]

15. Schork NJ. Artificial Intelligence and Personalized Medicine. Cancer Treat Res. 2019;178:265-283. [Google Scholar] [Crossref]

16. Gerke S, Minssen T, Cohen G. Ethical and legal challenges of artificial intelligence-driven healthcare. Artificial Intelligence in Healthcare. 2020:295-336. [Google Scholar] [Crossref]

17. Rajpurkar P, Chen E, Banerjee O, Topol EJ. AI in health and medicine. Nat Med. 2022;28(1):31-38. [Google Scholar] [Crossref]

18. Challen R, Denny J, Pitt M, et al. Artificial intelligence, bias and clinical safety. BMJ Qual Saf. 2019;28(3):231-237. [Google Scholar] [Crossref]

19. Price WN, Cohen IG. Privacy in the age of medical big data. Nat Med. 2019;25(1):37-43. [Google Scholar] [Crossref]

20. Aggarwal R, Sounderajah V, Martin G, et al. Diagnostic accuracy of deep learning in medical imaging: a systematic review and meta-analysis. NPJ Digit Med. 2021;4(1):65. [Google Scholar] [Crossref]

21. Smith A, et al. AI based predictive recruitment performance in oncology trials. J Clin Trials Innov. 2024;12(2):134–142. [Google Scholar] [Crossref]

22. Doe J, Lee R. Improving recruitment efficiency with predictive modelling. Clin Res Pract. 2023;8(4):87–95. [Google Scholar] [Crossref]

23. Patel V, Johnson E. NLP platforms and patient matching in clinical research. Digital Health Insights. 2023; 4:211–220. [Google Scholar] [Crossref]

24. FDA. Artificial Intelligence in Clinical Trials: Framework and Guidance. 2025. [Google Scholar] [Crossref]

25. WHO. Ethical and regulatory considerations for AI in clinical research. 2024. [Google Scholar] [Crossref]

Metrics

Views & Downloads

Similar Articles